The phase II clinical study EV-201 evaluating the antibody-drug conjugate Padcev (enfortumab vedotinejfv) for treatment of urothelial cancer demonstrated a 52% overall response rate in the second cohort.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
